Delayed Photoionization Feedback in a Super Star Cluster in SBS0335-052E

SBS0335-052 is a well studied Blue Compact Dwarf galaxy with one of the lowest metallicities of any known galaxy. It also contains 6 previously identified Super Star Clusters. We combine archival HST NICMOS images in the Pa alpha line and the 1.6 micron continuum of the eastern component, SBS0335-052E, with other space and ground based data to perform a multi-wavelength analysis of the super star clusters. We concentrate on the southern most clusters, designated S1 and S2, which appear to be the youngest clusters and are the strongest emitters of Pa alpha, radio, and x-ray flux. Our analysis leads to a possible model for S1 and perhaps S2 as a cluster of very young, massive stars with strong stellar winds. The wind density can be high enough to absorb the majority of ionizing photons within less than 1000 AU of the stars, creating very compact HII regions that emit optically thick radiation at radio wavelengths. These winds would then effectively quench the photoionizing flux very close to the stars. This can delay the onset of negative feedback by photoionization and photodissociation on star formation in the clusters. This is significant since SBS0335-052E resembles the conditions that were probably common for high redshift star formation in galaxies near the epoch of reionization.Comment: Accepted for publication in the Astrophysical Journa

Super Star Clusters in SBS0335-052E

As one of the lowest metallicity star forming galaxies, with a nucleus of several super star clusters, SBS0335-052E is the subject of substantial current study. We present new insights on this galaxy based on new and archival high spatial resolution NICMOS and ACS images. We provide new measurements and limits on the size of several of the SSCs. The images have sufficient resolution to divide the star formation into compact regions and newly discovered extended regions, indicating a bi-modal form of star formation. The star formation regions are dated via the equivalent width of the Pa alpha emission and we find that two of the extended regions of star formation are less than 10 million years old. Our previous finding that stellar winds confine the photo-ionizing flux to small regions around individual stars is consistent with the new observations. This may allow planet formation in what would traditionally be considered a harsh environment and has implications for the number of planets around globular cluster stars. In addition the images pinpoint the regions of H2 emission as located in, but not at the center of the two star forming super star clusters, S1 and S2.Comment: Accepted by the Astrophysical Journa

Electron precipitation from EMIC waves: a case study from 31 May 2013

On 31 May 2013 several rising-tone electromagnetic ion-cyclotron (EMIC) waves with intervals of pulsations of diminishing periods (IPDP) were observed in the magnetic local time afternoon and evening sectors during the onset of a moderate/large geomagnetic storm. The waves were sequentially observed in Finland, Antarctica, and western Canada. Co-incident electron precipitation by a network of ground-based Antarctic Arctic Radiation-belt Dynamic Deposition VLF Atmospheric Research Konsortia (AARDDVARK) and riometer instruments, as well as the Polar-orbiting Operational Environmental Satellite (POES) electron telescopes, was also observed. At the same time POES detected 30-80 keV proton precipitation drifting westwards at locations that were consistent with the ground-based observations, indicating substorm injection. Through detailed modelling of the combination of ground and satellite observations the characteristics of the EMIC-induced electron precipitation were identified as: latitudinal width of 2-3° or ΔL=1 Re, longitudinal width ~50° or 3 hours MLT, lower cut off energy 280 keV, typical flux 1×104 el. cm-2 sr-1 s-1 >300 keV. The lower cutoff energy of the most clearly defined EMIC rising tone in this study confirms the identification of a class of EMIC-induced precipitation events with unexpectedly low energy cutoffs of <400 keV

Platelet Glycoprotein lib: Chromosomal Localization and Tissue Expression

The GPIIb-IIIa complex functions as a receptor for cytoadhesive proteins on the platelet surface. Both GPIIb and GPIIIa are synthesized by a human erythroleukemia (HEL) cell line. We isolated several cDNA clones by screening a HEL cell cDNA library with an oligonucleotide derived from amino acid sequence of GPIIb. Nucleotide and amino acid sequences were determined from 703 bp of one of these clones. Amino acid sequence of purified platelet GPIIb peptides confirmed the identity of the clone. The cDNA encodes the carboxyl terminus of the large (a) subunit of GPIIb and all of the smaller (f6) subunit of GPIIb. By hybridizing the cDNA directly to chromosomes separated by dual laser chromosome sorting, the gene for GPIIb was mapped to chromosome 17. Northern blot analysis showed a - 3.4-kb GPIIb mRNA in HEL cells. We also compared the amino acid sequences determined from eight additional platelet GPIIb peptides with the derived amino acids from a published HEL cell GPIIb cDNA, and the platelet and HEL cell proteins appear to be the same. Despite previous reports that vascular endothelial cells and monocytes contain GPIIb, no GPIIb mRNA was observed in either type of cell. Thus, GPIIb appears to be specific for the platelet-megakaryocyte membrane and is distinct from the a subunits of the adhesion receptors in other normal tissues

Diagnostic randomized controlled trials: the final frontier

Abstract Clinicians, patients, governments, third-party payers, and the public take for granted that diagnostic tests are accurate, safe and effective. However, we may be seriously misled if we are relying on robust study design to ensure accurate, safe, and effective diagnostic tests. Properly conducted, randomized controlled trials are the gold standard for assessing the effectiveness and safety of interventions, yet are rarely conducted in the assessment of diagnostic tests. Instead, diagnostic cohort studies are commonly performed to assess the characteristics of a diagnostic test including sensitivity and specificity. While diagnostic cohort studies can inform us about the relative accuracy of an experimental diagnostic intervention compared to a reference standard, they do not inform us about whether the differences in accuracy are clinically important, or the degree of clinical importance (in other words, the impact on patient outcomes). In this commentary we provide the advantages of the diagnostic randomized controlled trial and suggest a greater awareness and uptake in their conduct. Doing so will better ensure that patients are offered diagnostic procedures that will make a clinical difference.</jats:p

Exploring the NRO Opportunity for a Hubble-sized Wide-field Near-IR Space Telescope -- NEW WFIRST

We discuss scientific, technical and programmatic issues related to the use of an NRO 2.4m telescope for the WFIRST initiative of the 2010 Decadal Survey. We show that this implementation of WFIRST, which we call "NEW WFIRST," would achieve the goals of the NWNH Decadal Survey for the WFIRST core programs of Dark Energy and Microlensing Planet Finding, with the crucial benefit of deeper and/or wider near-IR surveys for GO science and a potentially Hubble-like Guest Observer program. NEW WFIRST could also include a coronagraphic imager for direct detection of dust disks and planets around neighboring stars, a high-priority science and technology precursor for future ambitious programs to image Earth-like planets around neighboring stars.Comment: 76 pages, 26 figures -- associated with the Princeton "New Telescope Meeting

Management of pregnancy associated venous-thromboembolism: a survey of practices

Abstract Introduction Low-molecular-weight heparin (LMWH) is frequently recommended for the treatment of pregnancy associated venous thromboembolism (PAVTE). Given that prior reports have suggested a wide variation in dosing of LMWH in pregnancy and the use of anti-Xa monitoring in pregnancy, the principal aim of this survey was to assess current practices for the management of PAVTE. Methods An electronic survey was conducted. The target sample was members of the North American Society of Obstetric Medicine and Thrombosis Interest Group of Canada. Results The final sample consisted of 27/69 hematologists (39.1%), 30/69 internists (43.5%), 8/69 obstetricians (11.6%), and 4/69 from other specialties (5.7%). For the acute treatment of patients pregnant patients with deep vein thrombosis 42/69 (60.8%) preferred LMWH given twice a day 42/69 (60.8%), whereas 25/69 (36.2%) preferred once daily. These results were similar for patients with pulmonary embolism (PE). For long-term treatment more than 70% of the respondents favoured treatment with full doses of LMWH given once a day or twice a day and 16/69 (23.2%) intermediate doses for patients diagnosed with DVT. These results were similar for patients with PE. Fourteen physicians out of 69 (20.3%) did not measure anti-Xa monitoring during acute treatment period and 24/69 (34.8%) never used anti-Xa levels during the long term treatment period. Management during the peri-partum period varied widely according to the time of the diagnosis of PAVTE. Discussion In conclusion, our survey shows wide variation in practice regarding LMWH dosing and anti-Xa monitoring in pregnancy associated VTE and calls for trials comparing different long term strategies using LMWH in patients with PAVTE

Protocol for a modelling study to assess the clinical and cost-effectiveness of indefinite anticoagulant therapy for first unprovoked venous thromboembolism.

INTRODUCTION Deciding whether to stop or extend anticoagulant therapy indefinitely after completing at least 3 months of initial treatment for a first unprovoked venous thromboembolism (VTE) remains a challenge for clinicians, patients and policy makers. Guidelines suggest an indefinite duration of anticoagulant therapy in these patients, yet its benefits, harms and costs have not been formally assessed. The aim of this proposed modelling study is to assess the differences in clinical benefits, harms and costs of stopping versus continuing anticoagulant therapy indefinitely for a first unprovoked VTE. METHODS AND ANALYSIS We will develop a probabilistic Markov model, adopting a 1-month cycle length and a lifetime horizon, to estimate life-years, quality-adjusted life-years, costs and the incremental cost-effectiveness ratios for a simulated population of patients with a first unprovoked VTE who will receive indefinite duration of anticoagulant therapy versus a population who will not receive extended treatment after completing 3 months of initial anticoagulant therapy. The economic evaluation will adopt a third-party payer perspective relating to a Canadian publicly funded healthcare system. Estimates for the probability of relevant clinical events will be informed by systematic reviews and meta-analyses, while costs and utility values will be obtained from published Canadian sources. Stratified analyses based on sex, age and site of initial VTE will also be performed to identify subgroups of patients with a first unprovoked VTE in whom continuing anticoagulant therapy indefinitely might prove to be clinically beneficial and cost-effective over stopping treatment. We will also conduct sensitivity and scenario analyses to assess robustness of study findings to changes in individual or groups of key parameters. ETHICS AND DISSEMINATION Ethical approval is not applicable for this study. The results will be disseminated through presentations at relevant conferences and in a manuscript that will be submitted to a peer-reviewed journal